Hypertension
1 COMMENT - Jun 29, 2009 16:00 EDT
White-coat hypertension and masked hypertension should not be regarded as benign, say the authors of a new 10-year study. The risk of developing sustained hypertension is higher in people with the above two conditions than in those who have normal blood pressure, they found.

Milan, Italy - White-coat hypertension and masked hypertension should not be regarded as benign, say the authors of a new study [1]. Dr Giuseppe Mancia (University Milan-Bicocca, Monza, Italy ) and colleagues show in their 10-year trial, published online June 29, 2009 in Hypertension, that the risk of developing sustained hypertension is significantly higher in people with one of the above two conditions than in those who have normal blood pressure. Read full article »

 
heartbriefs
Jul 2, 2009 12:45 EDT
Smoking-cessation drugs varenicline and bupropion must carry a boxed warning in their labeling stating that use of the drugs has been associated with serious mental-health events, the US FDA has announced.
Arrhythmia/EP
Jul 1, 2009 17:00 EDT
An analysis of Medicare records for over 433 000 patients who received CPR between 1992 and 2005 showed that the rate of survival to hospital discharge hovered at around 18%, in spite of efforts to improve CPR delivery.
Lipid/Metabolic
9 COMMENTS - Jun 30, 2009 19:01 EDT
A new meta-analysis including some of the more contemporary statin trials has found that the agents significantly improve survival and reduce coronary and cardiovascular end points in primary-prevention populations, a benefit that extends to all subgroups. But the exact cost/benefit equation for each group remains to be determined.
Clinical cardiology
4 COMMENTS - Jun 30, 2009 16:00 EDT
Screening for contemporary biomarkers, such as CRP, will not add much to conventional cardiovascular risk factors in terms of helping to predict future events in the primary-prevention setting, say the authors of a new study.
heartbriefs
1 COMMENT - Jun 30, 2009 15:15 EDT
The makers of alogliptin say it will be two years before they have the cardiovascular data needed by the FDA, while the EASD raises concerns over a possible cancer risk with insulin glargine.
heartbriefs
Jun 29, 2009 17:00 EDT
Study participants will be randomized to one of four groups: daily vitamin D (2000 IU) and fish oil (1 g); daily vitamin D and fish-oil placebo; daily vitamin-D placebo and fish oil; or daily vitamin-D placebo and fish-oil placebo and followed for five years.
Clinical cardiology
Jun 26, 2009 12:00 EDT
HIV infection per se is an independent risk factor for preclinical atherosclerosis, with the magnitude of the effect being similar to that of known risk factors, such as smoking and diabetes, a new study has shown.
Brain/Kidney/Peripheral
Jun 25, 2009 16:15 EDT
Researchers are reporting divergent patterns of cardiovascular events associated with the frequency of migraine attacks with aura: more frequent attacks are associated with higher stroke risk, lower frequencies with higher MI and revascularization.
Arrhythmia/EP
1 COMMENT - Jun 23, 2009 14:45 EDT
A new study has found that increasing severity of sleep apnea is associated with a progressive increase in the risk of nocturnal arrhythmias. In addition, different types of sleep apnea were associated with different kinds of arrhythmias.
Acute Coronary Syndromes
Jun 22, 2009 16:30 EDT
From 1994 to 2004, cardiovascular disease mortality declined 30%, while the rate of MI mortality decreased 38.1% and stroke mortality decreased 28.2%.
Clinical cardiology
5 COMMENTS - Jun 22, 2009 13:45 EDT
As well as being an independent risk factor for cardiovascular disease, psoriasis is also associated with an increased risk of cerebrovascular disease and peripheral arterial disease, a new case-control study has shown.
Editorial Programs
The Cardiology Show
Apr 2, 2009 15:35 EDT
Join Drs Valentin Fuster, Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf as they unravel the STICH trial and debate the lessons learned from PROTECT-AF in Part 1 of the Cardiology Show. In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.
Cardiology panels
Nov 4, 2008 14:31 EST
Dr Melissa Walton-Shirley asks Drs Franz Messerli and Raymond Gibbons for their thoughts on dual RAAS inhibition and on what the future holds for ACE inhibitors and angiotensin-receptor blockers following ONTARGET and TRANSCEND.
Cardiology panels
Oct 15, 2008 09:41 EDT
Join Drs Marc Pfeffer, Philip Poole-Wilson, and Franz Messerli, as they talk about the use of ARBs in patients intolerant of ACE inhibitors, following the unexpected results of the TRANSCEND study, in a spirited debate moderated by heartwire journalist Lisa Nainggolan.
button
Previews
Info from Industry
Poll
Would you previously have considered 35-44 year olds as the optimum target age group for primary prevention of ischemic stroke?
See: Susan Jeffrey. Frequency of ischemic stroke climbs steeply after the age of 40.
Yes
No